IGHE and chronic rhinosinusitis with nasal polyps: In recent years, biologic agents targeting Th2 immune responses, such as Omalizumab (anti-IgE), Mepolizumab (anti-IL-5), and Dupilumab (anti-IL-4 receptor α), have demonstrated effective treatment outcomes in CRSwNP patients (27–30).